Congress locks in drug discounts for hospitals, blocks pharma workarounds
S. 2372 — 340B PATIENTS Act of 2025 · Filed by Peter Welch (D-VT) · 2 cosponsors · Introduced Jul 22, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill clarifies that pharmaceutical manufacturers participating in the 340B drug discount program must offer discounted prices to covered entities (hospitals, clinics, health centers) regardless of how or where those drugs are dispensed—including through contract pharmacies. It prohibits manufacturers from imposing conditions that restrict where drugs can be delivered, how they can be purchased, or what data must be reported, and establishes civil penalties up to $2 million per day for violations.
Why we flagged it
The bill's core function is to clarify and enforce existing 340B program rights for covered entities and patients, preventing manufacturers from circumventing the discount program through contractual restrictions. It is fundamentally a patient-access and program-integrity measure, not a price-control or subsidy mechanism.
What the text implies
- Manufacturers may face significant compliance costs and legal exposure if they have been conditioning 340B discounts on dispensing restrictions; the $2M/day penalty creates strong incentive to cease such practices immediately.
- Contract pharmacies—particularly specialty and mail-order pharmacies—gain explicit legal protection to dispense 340B drugs without manufacturer interference, potentially expanding their market share in specialty drug distribution.
The full analysis lists 5 implications of this text.
Who stands to gain
covered entities (hospitals, clinics, health centers); contract pharmacies (specialty and mail-order); patients requiring specialty drugs